Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 4/4/2020
SIETES contiene 92956 citas

 1 a 20 de 104 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Strom BL, Schinnar R, Karlawish J, Hennessy S, Teal V, Bilker WB. Statin therapy and risk of acute memory impairment. JAMA Intern Med 2015;175:1399-405. [Ref.ID 99143]
2. Cita con resumen
Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, Hennessy S, Strom BL. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 2012;21:1155-72. [Ref.ID 93987]
3. Cita con resumen
Mamtanin R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. The Journal of National Cancer Institute 2012;104:1411-21. [Ref.ID 93131]
4. Cita con resumen
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S. Cardiovascular events and deaht in children exposed and unexposed to ADHD agents. Pediatrics 2011;127:1102-10. [Ref.ID 90716]
5.Enlace a cita original Cita con resumen
Lewis JD, Ferrara A, Peng T, Hederson M, Bilker WB, Quesenberry Jr CP, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone. Interim report of a longitudinal cohort study. Diabetes Care 2011;34:923-9. [Ref.ID 90425]
6. Cita con resumen
Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2009;18:730-6. [Ref.ID 86510]
7.Enlace a cita original
Haynes K, Hennessy S, Localio AR, Cohen A, Leornard CE, Kimmel SE, Feldman HI, Strom BL, Metlay JP. Increased risk of digoxin toxicity following hospitalization. Pharmacoepidemiol Drug Saf 2009;18:28-35. [Ref.ID 85179]
9.Enlace a cita original
Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Laskin MS, Kimmel SE. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf 2008;17:853-60. [Ref.ID 83991]
10.Enlace a cita originalTiene citas relacionadas
Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17:753-9. [Ref.ID 83891]
11.Tiene citas relacionadas
Strom BL, Lewis JD. In clarification. Pharmacoepidemiol Drug Saf 2007;16:1063-4. [Ref.ID 81532]
12. Cita con resumen
Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. [Ref.ID 79964]
13.Tiene citas relacionadas Cita con resumen
Hennessy S, Strom BL. PDUFA reauthorization - Drug safety's golden moment of opportunity?. N Engl J Med 2007;356:1703-4. [Ref.ID 79877]
14. Cita con resumen
Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety. A proposal for sweeping changes. Arch Intern Med 2006;166:1938-42. [Ref.ID 78303]
Strom BL. How the US drug safety system should be changed. JAMA 2006;295:2072-5. [Ref.ID 76912]
Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, Nessel L, Localio AR. Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure. Pharmacoepidemiol Drug Saf 2006;15:39-45. [Ref.ID 76036]
17. Cita con resumen
Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443-51. [Ref.ID 74370]
Strom BL. Statins and over-the-counter availability. N Engl J Med 2005;352:1403-5. [Ref.ID 73334]
19.Tiene citas relacionadas
Strom BL. Evaluation of suspected adverse drug reactions. In reply. JAMA 2005;293:1324-5. [Ref.ID 73173]
20.Tiene citas relacionadas Cita con resumen
Kimmel PL, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64. [Ref.ID 72722]
Seleccionar todas
 1 a 20 de 104 siguiente >>